Baillie Gifford & Co. Trims Holdings in Recursion Pharmaceuticals, Inc. $RXRX

Baillie Gifford & Co. decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,774,972 shares of the company’s stock after selling 203,723 shares during the quarter. Baillie Gifford & Co. owned about 4.57% of Recursion Pharmaceuticals worth $97,240,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of RXRX. Brighton Jones LLC raised its position in Recursion Pharmaceuticals by 49.4% in the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after purchasing an additional 6,699 shares during the last quarter. Royal Bank of Canada raised its position in Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after buying an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth purchased a new position in Recursion Pharmaceuticals during the 1st quarter worth $77,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 4.3%

Shares of Recursion Pharmaceuticals stock opened at $3.42 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50. Recursion Pharmaceuticals, Inc. has a one year low of $2.80 and a one year high of $7.18. The company has a market cap of $1.80 billion, a P/E ratio of -2.31 and a beta of 1.02. The firm has a fifty day moving average of $3.44 and a two-hundred day moving average of $4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The business had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $24.56 million. During the same period in the prior year, the company posted ($0.53) EPS. The business’s revenue for the quarter was up 671.7% on a year-over-year basis. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 28,298 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30. Following the transaction, the chief executive officer directly owned 2,262,085 shares of the company’s stock, valued at $7,577,984.75. This represents a 1.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Blake Borgeson sold 220,000 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total transaction of $924,000.00. Following the transaction, the director directly owned 6,429,863 shares in the company, valued at approximately $27,005,424.60. This trade represents a 3.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 299,680 shares of company stock valued at $1,180,121 in the last ninety days. 8.43% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. Bank of America cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Finally, Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.